SOAT1 and Alzheimer disease: Due to the crucial role of the activation of the JAK/STAT pathway in AD pathogenesis, its inhibition through JAK inhibitors (JAKi) represents a current target of recently approved drugs, and several others are in the pipeline, with encouraging results (Table 1 and Table 2) [20].